- In March 2025, Johnson & Johnson announced a Phase III trial initiation for its anti-CD20 monoclonal antibody therapy aimed at patients with refractory AIHA across North America and Europe
- In August 2024, Novartis reported promising early-stage results for an investigational Syk inhibitor therapy targeting warm AIHA, showing improved hemoglobin levels and reduced hemolysis in preliminary cohorts
